Trials / Completed
CompletedNCT01064453
Angeliq Regulatory Post Marketing Surveillance
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,078 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Angeliq regulatory Post-Marketing Surveillance (PMS) is to get data about safety and efficacy in real practice for the indication approved by Korea Food and Drug Administration (KFDA). This is non-interventional , prospective, multi-center study.Target number of patients is 4500.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E2/DRSP (Angeliq, BAY86-4891) | Take one tablet daily, continuously |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2010-02-08
- Last updated
- 2013-11-19
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01064453. Inclusion in this directory is not an endorsement.